Добавил:
Upload Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Prescriber's Guide_ Stahl's Ess - Stephen M. Stahl.docx
Скачиваний:
1
Добавлен:
01.07.2025
Размер:
3 Мб
Скачать
☆

List of icons

alcohol dependence treatment

alpha adrenergic blocker

alpha 2 agonist

anticonvulsant

antihistamine

antiparkinson/anticholinergic

benzodiazepine

beta blocker

cholinesterase inhibitor

conventional antipsychotic

dopamine stabilizer

lithium

lorcaserin

medical food

l-methylfolate

modafinil (wake-promoter)

monoamine oxidase inhibitor

nefazodone (serotonin antagonist/reuptake inhibitor)

nicotinic partial agonist

N-methyl-D-aspartate antagonist

noradrenergic and specific serotonergic antidepressant

norepinephrine and dopamine reuptake inhibitor

sedative-hypnotic

selective norepinephrine reuptake inhibitor

selective serotonin reuptake inhibitor

serotonin-dopamine antagonist

serotonin and norepinephrine reuptake inhibitor

serotonin 1A partial agonist

serotonin partial agonist reuptake inhibitor

sodium oxybate

stimulant

thyroid hormone

topiramate/phentermine

trazodone (serotonin antagonist/reuptake inhibitor)

tricyclic/tetracyclic antidepressant

vortioxetine

How the drug works, mechanism of action

Best augmenting agents to add for partial response or treatment-resistance

Life-threatening or dangerous side effects

Weight Gain: Degrees of weight gain associated with the drug, with unusual signifying that weight gain has been reported but is not expected; not unusual signifying that weight gain occurs in a significant minority; common signifying that many experience weight gain and/or it can be significant in amount; and problematic signifying that weight gain occurs frequently, can be significant in amount, and may be a health problem in some patients

Sedation: Degrees of sedation associated with the drug, with unusual signifying that sedation has been reported but is not expected; not unusual signifying that sedation occurs in a significant minority; common signifying that many experience sedation and/or it can be significant in amount; and problematic signifying that sedation occurs frequently, can be significant in amount, and may be a health problem in some patients

Tips for dosing based on the clinical expertise of the author

Drug interactions that may occur

Warnings and precautions regarding use of the drug

Dosing and other information specific to children and adolescents

Information regarding use of the drug during pregnancy

Clinical pearls of information based on the clinical expertise of the author

The art of switching

Suggested reading

ACAMPROSATE

ACAMPROSATE: THERAPEUTICS

Brands

• Campral

see index for additional brand names

Generic?

Not in U.S.

Class

• Alcohol dependence treatment

Commonly Prescribed for

(bold for FDA approved)

• Maintenance of alcohol abstinence

How the Drug Works

• Theoretically reduces excitatory glutamate neurotransmission and increases inhibitory gamma-aminobutyric acid (GABA) neurotransmission

• Binds to and blocks certain glutamate receptors, including metabotropic glutamate receptors

• Because withdrawal of alcohol following chronic administration can lead to excessive glutamate activity and deficient GABA activity, acamprosate can act as “artificial alcohol” to mitigate these effects

How Long Until It Works

• Has demonstrated efficacy in trials lasting between 13 and 52 weeks

If It Works

• Increases abstinence from alcohol

If It Doesn’t Work

• Evaluate for and address contributing factors

• Consider switching to another agent

• Consider augmenting with naltrexone

Best Augmenting Combos for Partial Response or Treatment Resistance

• Naltrexone

• Augmentation therapy may be more effective than monotherapy

• Augmentation with behavioral, educational, and/or supportive therapy in groups or as an individual is probably key to successful treatment

Tests

• None for healthy individuals

ACAMPROSATE: SIDE EFFECTS

How Drug Causes Side Effects

• Theoretically, behavioral side effects due to changes in neurotransmitter concentrations at receptors in parts of the brain and body other than those that cause therapeutic actions

• Gastrointestinal side effects may be related to large doses of a drug that is an amino acid derivative, increasing osmotic absorption in the GI tract

Notable Side Effects

• Diarrhea, nausea

• Anxiety, depression

Life-Threatening or Dangerous Side Effects

• Suicidal ideation and behavior (suicidality)

Weight Gain

• Reported but not expected

Sedation

• Reported but not expected

What to Do About Side Effects

• Wait

• Adjust dose

• If side effects persist, discontinue use

Best Augmenting Agents for Side Effects

• Dose reduction or switching to another agent may be more effective since most side effects cannot be improved with an augmenting agent

ACAMPROSATE: DOSING AND USE

Usual Dosage Range

• 666 mg three times daily (>60 kg)

• 666 mg two times daily (<60 kg)

Dosage Forms

• Tablet 333 mg

How to Dose

• Patient should begin treatment as soon as possible after achieving abstinence

• Recommended dose is 666 mg three times daily; titration is not required

Dosing Tips

• Providing educational materials and counseling in combination with acamprosate treatment can increase the chances of success

• Patients should be advised to continue treatment even if relapse occurs and to disclose any renewed drinking

• Although absorption of acamprosate is not affected by food, it may aid adherence if patients who regularly eat three meals per day take each dose with a meal

• Adherence with three times daily dosing can be a problem; having patient focus on frequent oral dosing of drug rather than frequent drinking may be helpful in some patients

Overdose

• Limited available data; diarrhea

Long-Term Use

• Has been studied in trials up to one year

Habit Forming

• No

How to Stop

• Taper not necessary

Pharmacokinetics

• Terminal half-life 20–33 hours

• Excreted unchanged via the kidneys

Drug Interactions

• Does not inhibit hepatic enzymes, and thus is unlikely to affect plasma concentrations of drugs metabolized by those enzymes

• Is not hepatically metabolized and thus is unlikely to be affected by drugs that induce or inhibit hepatic enzymes

• Concomitant administration with naltrexone may increase plasma levels of acamprosate, but this does not appear to be clinically significant and dose adjustment is not recommended

Other Warnings/Precautions

• Monitor patients for emergence of depressed mood or suicidal ideation and behavior (suicidality)

• Use cautiously in individuals with known psychiatric illness

Do Not Use

• If patient has severe renal impairment

• If there is a proven allergy to acamprosate

ACAMPROSATE: SPECIAL POPULATIONS

Renal Impairment

• For moderate impairment, recommended dose is 333 mg three times daily

• Contraindicated in severe impairment

Hepatic Impairment

• Dose adjustment not generally necessary

Cardiac Impairment

• Limited data available

Elderly

• Some patients may tolerate lower doses better

• Consider monitoring renal function

Children and Adolescents

• Safety and efficacy have not been established

Pregnancy

• Risk Category C [some animal studies show adverse effects; no controlled studies in humans]

• Pregnant women needing to stop drinking may consider behavioral therapy before pharmacotherapy

• Not generally recommended for use during pregnancy, especially during first trimester

Breast Feeding

• Unknown if acamprosate is secreted in human breast milk, but all psychotropics assumed to be secreted in breast milk

• Recommended either to discontinue drug or bottle feed

ACAMPROSATE: THE ART OF PSYCHOPHARMACOLOGY

Potential Advantages

• Individuals who have recently abstained from alcohol

• For the chronic daily drinker

Potential Disadvantages

• Individuals who are not abstinent at time of treatment initiation

• For binge drinkers

Primary Target Symptoms

• Alcohol dependence

Pearls

• Because acamprosate serves as “artificial alcohol,” it may be less effective in situations in which the individual has not yet abstained from alcohol or suffers a relapse

• Thus acamprosate may be a preferred treatment if the goal is complete abstinence, but may not be preferred if the goal is reduced-risk drinking

Suggested Reading

Anton RF, O’Malley SS, Ciraulo DA et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006;295(17):2003–17.

Kranzler HR, Gage A. Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. Am J Addictions 2008; 17:70–6.

Rosner S, Leucht P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a met-analysis with unreported outcomes. J Psychopharmacol 2008;22:11–23.

AGOMELATINE

AGOMELATINE: THERAPEUTICS

Brands

• Valdoxan

see index for additional brand names

Generic?

No

Class

• Agonist at melatonergic 1 and melatonergic 2 receptors

• Antagonist at 5HT2C receptors

Commonly Prescribed for

(bold for FDA approved)

• Depression

• Generalized anxiety disorder

How the Drug Works

• Actions at both melatonergic and 5HT2C receptors may be synergistic and increase norepinephrine and dopamine neurotransmission in the prefrontal cortex; may resynchronize circadian rhythms that are disturbed in depression

• No influence on extracellular levels of serotonin

How Long Until It Works

• Daytime functioning, anhedonia, and sleep can improve from the first week of treatment

• Onset of full therapeutic actions in depression is usually not immediate, but often delayed 2–4 weeks

• May continue to work for many years to prevent relapse of symptoms

If It Works

• The goal of treatment is complete remission of current symptoms as well as prevention of future relapses

• Treatment most often reduces or even eliminates symptoms, but not a cure since symptoms can recur after medicine is stopped

• Continue treatment until all symptoms are gone (remission)

• Once symptoms gone, continue treating for 1 year for the first episode of depression

• For second and subsequent episodes of depression, treatment may need to be indefinite

Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]